CLVS - Clovis Oncology - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

634.1M

Cash

58.32M

Avg Qtr Burn

-43.89M

Short % of Float

20.03%

Insider Ownership

1.44%

Institutional Own.

25.90%

Qtr Updated

09/30/22

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rucaparib (Rubraca®) Details Ovarian cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rucaparib (Rubraca®) Details Prostate cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rucaparib (Rubraca®) Details Cancer, Prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.